Transgene SA

0,7030

23-декабря-24 11:17:32

15 мин. задержка

Акции

0,0000

0,00%

Сегодняшний диапазон

0,7030 - 0,7030

ISIN

FR0005175080

Источник

Cboe

Transgene and NEC Present First Clinical Benefits of Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at AACR 2024

09 апр 2024 11:45:00 Источник Nasdaq GlobeNewswire
Transgene anticipates significant progress from immunotherapy pipeline in 2024 and extends financial visibility until Q4 2025

27 мар 2024 12:45:00 Источник Nasdaq GlobeNewswire
Transgene appoints Lucie Larguier as Chief Financial Officer and Christelle Schwoerer as Chief Human Resources Officer

27 мар 2024 12:45:00 Источник Nasdaq GlobeNewswire
Transgene Announces Upcoming Investor Meetings

18 мар 2024 12:45:00 Источник Nasdaq GlobeNewswire
Transgene to Present New Data on TG4050, an Individualized Cancer Vaccine, at AACR 2024

06 мар 2024 01:30:00 Источник Nasdaq GlobeNewswire
Transgene, NEC, and BostonGene Expand Collaboration for Phase I/II Clinical Trial of Neoantigen Cancer Vaccine TG4050

05 мар 2024 01:30:00 Источник Nasdaq GlobeNewswire
Transgene Further Strengthens Management Team with Appointment of James Wentworth as Chief Business Officer

22 янв 2024 11:45:00 Источник Nasdaq GlobeNewswire
Transgene Announces Financial Calendar for 2024

22 янв 2024 02:00:00 Источник Nasdaq GlobeNewswire
Transgene and NEC Extend their Collaboration to Continue Joint Clinical Development of Neoantigen Cancer Vaccine TG4050

08 янв 2024 11:45:00 Источник Nasdaq GlobeNewswire
Balance sheet of the liquidity contract with Natixis Oddo BHF SCA as of December 31, 2023

04 янв 2024 11:45:00 Источник Nasdaq GlobeNewswire

<<
<
1
2
>

Принимаю NetDania's website uses cookies. By continuing browsing our website, you agree to our Правила в отношении Cookies, Политика конфиденциальности and Правила и условия.